Date Title Description PDF
23 Nov 2022 On business and financial situation The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day   Download
04 Nov 2022 On business and financial situation The Company releases the press release related to the first nine months of 2022 financial results Download
04 Nov 2022 On business and financial situation The Company releases the first nine months 2022 financial results presentation Download
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
14 Mar 2022 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download

Pages

Date Title Description PDF
12 Mar 2024 On business and financial situation ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies Download
08 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 March and 7 March 2024 Download
07 Mar 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives  Download
01 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February and 29 February 2024 Download
27 Feb 2024 Annual Financial Reports and Audit Reports The Company submits the 2023 Annual Financial Report  Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages